Aldevron's Facility Expansion to Create 30 New Jobs By End of 2016

Aldevron Expands North Dakota Biomanufacturing Facility

Project to Support the Increasing Demand for Gene Therapy and Gene Editing Products

FARGO, N.D.--(BUSINESS WIRE)--Aldevron announced the completion of a 4,500-square-foot expansion of its GMP and GMP-Source™ biological manufacturing facilities in Fargo, North Dakota. The project increases the company’s available production capacity by over 35%. This expansion is in response to increasing demand for Aldevron’s custom plasmid, therapeutic RNA transcript, and enzyme services, and affirms the Company's position as a global leader in contract manufacturing for the biopharmaceutical industry. Aldevron’s products are used in a wide array of gene therapy, gene editing, and immunotherapy programs.

“We are excited to expand our footprint in Fargo and provide our clients with a consistent supply of the highest quality products and services”

Aldevron’s operations began in a laboratory at North Dakota State University in 1998 and have grown to include sites in Fargo, Madison, Wisconsin, and Freiburg, Germany. The Fargo site currently employs over 100 people and the company expects to increase its headcount to 130 by the end of 2016.

“We are excited to expand our footprint in Fargo and provide our clients with a consistent supply of the highest quality products and services,” said CEO Michael Chambers. “The entire community can be proud of our increased manufacturing capacity, which enable us to serve a rapidly growing number of clients.” Chambers added that the new facility is already being used to make GMP enzymes.

Aldevron began the expansion at its South Fargo campus last December 2015. Nordick Construction served as the general contractor for the project.

About Aldevron
Aldevron offers development services and custom manufacturing of nucleic acids, proteins and antibodies -- providing companies with essential components for research, clinical and commercial gene therapy and gene editing applications. Aldevron’s services include research/preclinical grade, GMP-Source™ and GMP plasmid manufacturing, linear DNA and mRNA production, gene synthesis, RNA synthesis enzymes, and human and recombinant antibody generation. Aldevron’s commitment to innovation, collaboration, and quality allow it to advance science by meeting precise client requirements. Aldevron is headquartered in Fargo, North Dakota, and has facilities in Madison, Wisconsin, and Freiburg, Germany.


Victoria Chambers, 701-306-2675
Director of Marketing and Communications

Back to news